During Monday’s Morning trade, Shares of Alcoa Inc. (NYSE:AA), lost -1.59% to $11.74, hitting its lowest level.
Alcoa Inc., declared that its innovative products and transformation strategy are delivering strong sustainability results. The achievements are highlighted in Alcoa’s 2014 Sustainability Report.
Over the last year, the Company expanded its multi-material value-add portfolio and introduced innovations across its end markets enabling customers to produce more environmentally friendly products. Alcoa also continued to reshape its commodity business to become more globally competitive by closing and curtailing high-cost, less efficient facilities, reducing its overall emissions.
The following are among the Company’s achievements highlighted in the 2014 Sustainability Report:
- Alcoa Innovations Put Sustainable Products on the Fast Track: In 2014, Alcoa unveiled a jet engine first— the world’s first advanced aluminum alloy fan blade forging for Pratt & Whitney’s Hybrid-Metallic Fan Blade, which will assist make Pratt & Whitney’s PurePower® engines lighter and more fuel efficient. In automotive, Alcoa’s breakthrough MicromillTM technology will enable the manufacture of automotive parts twice as formable and 30 percent lighter than parts made from high-strength steel, supporting the creation of lighter, more fuel efficient, safer and more stylish vehicles for the future. In commercial transportation, Alcoa’s new Ultra ONETM heavy-duty truck wheel is 47 percent lighter than a steel wheel of the same size and assists trucks enhance payload and fuel efficiency.
- Alcoa’s Environmental Footprint Continues to Shrink: Through energy-efficiency improvements, in addition to closures and curtailments of less-efficient facilities, Alcoa reduced its absolute greenhouse gas emissions by 3 million metric tons, or 6.8 percent, in 2014. For every metric ton of aluminum Alcoa makes recently, it emits 25.9 percent less greenhouse gases than it did in 2005.
- World-class Health and Safety Culture Delivers Results: The Company continued to invest in the safety, health, and well-being of its employees and their families. Regrettably, we suffered one contractor fatality during 2014. Alcoa’s days away, restricted, and transfer (DART) rate improved 8.3 percent from 2013. Wellness remained a key focus, with Alcoa being named the World’s Most Active Organization by the Global Corporate Challenge for the second successive year.
Alcoa Inc. produces and manages primary aluminum, fabricated aluminum, and alumina worldwide. The company operates through four segments: Alumina, Primary Metals, Global Rolled Products, and Engineered Products and Solutions.
Shares of Morgan Stanley (NYSE:MS), inclined 1.27% to $39.87, during its current trading session.
Morgan Stanley, declared a regular dividend on the outstanding shares of each of the following preferred stock issues:
- Floating Rate Non-Cumulative Preferred Stock, Series A - $252.78 per share (equivalent to $0.25278 per Depositary Share)
- 10 Percent Non-Cumulative Non-Voting Perpetual Preferred Stock, Series C - $25.00 per share
- Fixed-to-Floating Rate Non-Cumulative Preferred Stock, Series E - $445.31 per share (equivalent to $0.44531 per Depositary Share)
- Fixed-to-Floating Rate Non-Cumulative Preferred Stock, Series F - $429.69 per share (equivalent to $0.42969 per Depositary Share)
- 625 Percent Non-Cumulative Preferred Stock, Series G - $414.06 per share (equivalent to $0.41406 per Depositary Share)
- Fixed-to-Floating Rate Non-Cumulative Preferred Stock, Series H - $681.25 per share (equivalent to $27.25000 per Depositary Share)
- Fixed-to-Floating Rate Non-Cumulative Preferred Stock, Series I - $398.44 per share (equivalent to $0.39844 per Depositary Share)
- Fixed-to-Floating Rate Non-Cumulative Preferred Stock, Series J - $447.08 per share (equivalent to $17.88333 per Depositary Share)
The dividends for the Preferred Stock Series A, C, E, F, G, H, I and J are payable on July 15, 2015 to stockholders of record at the close of business on June 30, 2015.
Morgan Stanley, a financial holding company, provides various financial products and services to corporations, governments, financial institutions, and individuals worldwide.
Finally, Eli Lilly and Company (NYSE:LLY), gained 0.81%, and is now trading at $83.30.
Eli Lilly and Company, declared that The Lancet Oncology has published results of the Phase III REACH trial that evaluated CYRAMZA® (ramucirumab) as a second-line treatment for people with hepatocellular carcinoma (HCC), also known as liver cancer. While the REACH trial’s primary endpoint of overall survival favored the CYRAMZA arm, it was not statistically significant. However, encouraging single-agent CYRAMZA activity was observed, with meaningful improvements in key secondary endpoints in addition to within certain patient subgroups.
The global, randomized, double-blind REACH trial contrast ramucirumab plus best supportive care to placebo plus best supportive care as a second-line treatment in patients with HCC after being treated with sorafenib in the first-line setting. Median overall survival (OS) was 9.2 months on the ramucirumab arm contrast to 7.6 months on the placebo arm (HR 0.866; 95% CI: 0.717-1.046; p=0.1391). While the median OS was not statistically significant, a prespecified subgroup of patients with an elevated baseline of alpha-fetoprotein (AFP) ≥400 ng/mL showed a greater survival improvement with ramucirumab treatment. Median OS in this subgroup of patients was 7.8 months in the ramucirumab arm contrast to 4.2 months in the placebo arm (HR 0.674; 95% CI 0.508-0.895; p=0.0059).
The REACH study analyses presented at the Gastrointestinal Cancers Symposium earlier this year concluded that a greater reduction in the risk of death in patients with progressively higher baseline AFP values warrants further investigation. Based on these findings, Lilly will soon start enrollment in REACH-2, a new Phase III trial to evaluate the benefit of ramucirumab treatment in advanced liver cancer patients with an elevated baseline AFP (ClinicalTrials.gov identifier: NCT02435433).
Eli Lilly and Company discovers, develops, manufactures, and sells pharmaceutical products worldwide. It operates in two segments, Human Pharmaceutical Products and Animal Health products. The company offers endocrinology products to treat diabetes; osteoporosis in postmenopausal women and men; human growth hormone deficiency and pediatric growth conditions; and testosterone deficiency.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should/might occur.
